| Prognostic and predictive biomarkers in breast cancer: Past, present and future A Nicolini, P Ferrari, MJ Duffy Seminars in cancer biology 52, 56-73, 2018 | 421 | 2018 |
| Malnutrition, anorexia and cachexia in cancer patients: a mini-review on pathogenesis and treatment A Nicolini, P Ferrari, MC Masoni, M Fini, S Pagani, O Giampietro, A Carpi Biomedicine & Pharmacotherapy 67 (8), 807-817, 2013 | 232 | 2013 |
| Metastatic breast cancer: an updating A Nicolini, R Giardino, A Carpi, P Ferrari, L Anselmi, S Colosimo, M Conte, ... Biomedicine & pharmacotherapy 60 (9), 548-556, 2006 | 157 | 2006 |
| Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC) A Nicolini, PA Mancini, P Ferrari, L Anselmi, G Tartarelli, V Bonazzi, ... Biomedicine & pharmacotherapy 58 (8), 447-450, 2004 | 103 | 2004 |
| Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis A Antonelli, SM Ferrari, S Frascerra, A Di Domenicantonio, A Nicolini, ... The Journal of Clinical Endocrinology & Metabolism 96 (6), 1859-1863, 2011 | 92 | 2011 |
| Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15. 3 vs MCA and MCA-CA15. 3 vs CEA-TPA-CA15. 3 panel in the early detection of … A Nicolini, G Tartarelli, A Carpi, MR Metelli, P Ferrari, L Anselmi, M Conte, ... BMC cancer 6, 1-9, 2006 | 87 | 2006 |
| Sunitinib in the treatment of thyroid cancer SM Ferrari, M Centanni, C Virili, M Miccoli, P Ferrari, I Ruffilli, F Ragusa, ... Current medicinal chemistry 26 (6), 963-972, 2019 | 78 | 2019 |
| Cytokines in the management of high risk or advanced breast cancer: an update and expectation A Carpi, A Nicolini, A Antonelli, P Ferrari, G Rossi Current Cancer Drug Targets 9 (8), 888-903, 2009 | 73 | 2009 |
| Intensive risk-adjusted follow-up with the CEA, TPA, CA19. 9, and CA72. 4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences … A Nicolini, P Ferrari, MJ Duffy, A Antonelli, G Rossi, MR Metelli, F Fulceri, ... Archives of surgery 145 (12), 1177-1183, 2010 | 66 | 2010 |
| Molecular mechanisms, biomarkers and emerging therapies for chemotherapy resistant TNBC P Ferrari, C Scatena, M Ghilli, I Bargagna, G Lorenzini, A Nicolini International journal of molecular sciences 23 (3), 1665, 2022 | 62 | 2022 |
| The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy A Nicolini, P Ferrari, A Sagripanti, A Carpi British journal of cancer 79 (9), 1443-1447, 1999 | 62 | 1999 |
| Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: comparison between oral ferrous bisglycinate chelate and ferrous sulfate P Ferrari, A Nicolini, ML Manca, G Rossi, L Anselmi, M Conte, A Carpi, ... Biomedicine & Pharmacotherapy 66 (6), 414-418, 2012 | 61 | 2012 |
| Defective generation and maturation of dendritic cells from monocytes in colorectal cancer patients during the course of disease G Orsini, A Legitimo, A Failli, P Ferrari, A Nicolini, R Spisni, P Miccoli, ... International journal of molecular sciences 14 (11), 22022-22041, 2013 | 59 | 2013 |
| Stem cells: their role in breast cancer development and resistance to treatment A Nicolini, P Ferrari, M Fini, V Borsari, P Fallahi, A Antonelli, P Berti, ... Current pharmaceutical biotechnology 12 (2), 196-205, 2011 | 55 | 2011 |
| Immunotherapy and hormone-therapy in metastatic breast cancer: A review and an update A Nicolini, A Carpi, P Ferrari, P Mario Biava, G Rossi Current Drug Targets 17 (10), 1127-1139, 2016 | 45 | 2016 |
| Exosomes and cell communication: from tumour-derived exosomes and their role in tumour progression to the use of exosomal cargo for cancer treatment A Nicolini, P Ferrari, PM Biava Cancers 13 (4), 822, 2021 | 43 | 2021 |
| Quantification of blood dendritic cells in colorectal cancer patients during the course of disease G Orsini, A Legitimo, A Failli, P Ferrari, A Nicolini, R Spisni, P Miccoli, ... Pathology & Oncology Research 20, 267-276, 2014 | 42 | 2014 |
| Cancer: a problem of developmental biology; scientific evidence for reprogramming and differentiation therapy S Sell, A Nicolini, P Ferrari, P M Biava Current drug targets 17 (10), 1103-1110, 2016 | 39 | 2016 |
| Tumour growth and immune evasion as targets for a new strategy in advanced cancer A Nicolini, P Ferrari, G Rossi, A Carpi Endocrine-Related Cancer 25 (11), R577-R604, 2018 | 31 | 2018 |
| The PI3K-AKt-mTOR pathway and new tools to prevent acquired hormone resistance in breast cancer A Nicolini, P Ferrari, L Kotlarova, G Rossi, P M Biava Current pharmaceutical biotechnology 16 (9), 804-815, 2015 | 31 | 2015 |
Andrea NicoliniDepartment of Oncology, Transplantations and New Technologies in Medicine, University of Pisa, Pisa, Italy在 med.unipi.it 的电子邮件经过验证
